Zydus Completes Phase 2 Clinical Trial In Covid Patients With Biotherapy


Pharmaceutical company Zydus Cadila said on Thursday

he has successfully completed a Phase 2 clinical trial in COVID-19 patients with his biologic therapy, “PegiHep”, and will now begin a Phase 3 clinical trial.

In a regulatory filing, Zydus Cadila said “it has successfully completed a Phase 2 clinical trial in COVID-19 patients with its biologic therapy, pegylated interferon alpha-2b, ‘PegiHep’ … Based on the results of its phase 2 study, Zydus Cadila now plans to conduct a phase 3 clinical trial in India “.

Zydus Cadila, who is part of the Cadila Healthcare group, said that pegylated interferon alpha 2b significantly increases viral reduction and reduces the need for supplemental oxygen in moderate COVID-19 patients.

“We continue to examine possible treatment options that are safe and effective in the treatment and management of COVID-19. Pegylated interferon alpha-2b has shown the potential to reduce virus titers when given earlier in disease and we would like to explore this biological option. We hope to strengthen our treatment options to fight COVID-19, ”said Sharvil Patel, Managing Director of Cadila Healthcare Ltd.

Pegylated interferon alpha-2b is not a new therapy. The product was first approved internationally in 2001 and is also included in the WHO Essential Medicines List.

Zydus Cadila said his pegylated alpha-2b interferon, PegiHep, was initially approved for hepatitis C and was launched in the Indian market in 2011.

Since then, the safe and effective use of the drug for this product has been demonstrated in thousands of patients, the company added.

Zydus Cadila said he conducted this study on the Drugs Controller General of India (DCGI) approval to investigate the role of pegylated interferon alpha-2b for COVID 19. The company is also conducting a similar Phase 2 trial in Mexico. .

The company is also working with the United States Food and Drug Administration (USFDA) to open an Investigational New Drug Application (IND) for pegylated interferon alpha-2b to initiate appropriate clinical trials in the United States.

(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor


Leave A Reply